Exelgyn

What Exelgyn does

Exelgyn SAS is a privately held French pharmaceutical company headquartered at 216 boulevard Saint Germain, Paris, that develops, produces, and distributes a focused portfolio of reproductive women's health products centered on medical abortion. The company was established in 1997 to commercialize the first selective progesterone receptor modulator (SPRM) developed for gynecological use, tracing its scientific lineage to a 1970 Roussel-Uclaf research program that led to the discovery of mifepristone in 1980 and its launch as Mifegyne® in France in 1989. The core product offering consists of Mifegyne® (mifepristone tablets in 200 mg and 600 mg strengths) for antiprogesterone activity, MisoOne®/Topogyne®/Mispregnol® (400 mcg misoprostol scored oral tablets, a prostaglandin analogue with cervical contractility properties) for the second step of medical abortion regimens, and checkToP®, a low-sensitivity urinary hCG rapid diagnostic test for home pregnancy status determination.

The company monetizes through prescription pharmaceutical and medical device sales distributed almost entirely through Nordic Pharma, which acquired Exelgyn in 2010 after a 2007 distribution partnership and 2009 pan-European extension. End customers are healthcare professionals — primarily gynecologists, obstetricians, and medical facilities — and their patients in jurisdictions where abortion is legal and medical infrastructure exists; the products reach nearly 40 countries, with pricing not publicly disclosed. Exelgyn maintains an educational presence via its corporate website, the Abort-report.eu resource on European abortion legislation, and an active collaboration with FIAPAC (International Federation of Abortion & Contraception Professionals) for clinician education. The company is EU-MDR compliant, GDPR-compliant, and follows the ANSM French pharmaceutical internet communication charter.

The firm operates with a headcount in the 11–50 range, with no AI/ML capability, no consumer mobile apps, and no public revenue disclosure. Its strategic identity is that of a niche, single-therapeutic-area originator pharma asset embedded within a larger European specialty pharmaceutical group, where the value proposition rests on regulatory approvals accumulated over more than three decades, originator brand status, and an established institutional channel partner rather than on growth-stage technology differentiation.

Name

Exelgyn

Legal name

EXELGYN SAS

Website

https://exelgyn.com

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

11–50 employees

Short description

Exelgyn SAS is a privately held French pharmaceutical company specializing in reproductive women's health, marketing the originator mifepristone (Mifegyne®), misoprostol regimens (MisoOne®/Topogyne®/Mispregnol®), and a urinary hCG test (checkToP®) to healthcare professionals in nearly 40 countries through Nordic Pharma.

Ownership category

akta.pro rank

Product category

Reproductive Health Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medical Equipment and Supplies Manufacturing (3391)

SIC

Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro industry

PRIMARYHLAIACAN

Women’s Health & Reproductive Specialty Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Specialty Pharmaceuticals

SECONDARYHLAKAJAG

Family Planning & Contraception (Including Abortion Care)

Healthcare & Life Sciences/Specialist Medical Practice/Obstetrics & Gynecology (OB/GYN)

SECONDARYHLAHAOAF

Pregnancy, Fertility & Women’s Health Rapid Tests (hCG, ovulation, vaginal infection)

Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics

Keywords

• Medical abortion pharmaceuticals
• Reproductive health medicines
• Mifepristone tablets
• Misoprostol analogues
• Gynecological pharmaceuticals

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Exelgyn generates revenue through the sale of prescription pharmaceutical products for medical abortion care, including Mifegyne® (mifepristone), misoprostol products (MisoOne®, Topogyne®, Mispregnol®), and diagnostic tests (checkToP®).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Exelgyn develops, manufactures, and markets pharmaceutical products for medical abortion care in reproductive women's health. Its portfolio includes mifepristone (Mifegyne®, a selective progesterone receptor modulator in 200 mg and 600 mg dosages) and misoprostol (MisoOne®/Topogyne®/Mispregnol®, a 400 µg prostaglandin analogue), marketed primarily to healthcare professionals across nearly 40 countries. The company also offers checkToP®, a low-sensitivity urinary hCG rapid test for home use to confirm pregnancy status.

Product overview

Exelgyn is a pharmaceutical company specializing in reproductive women's health, providing a portfolio of medical abortion products. The core offerings include Mifegyne® (mifepristone in 200 mg and 600 mg formulations) — a selective progesterone receptor modulator (SPRM) with antiprogesterone activities — and MisoOne®/Topogyne®/Mispregnol® (misoprostol 400 μg tablets) — prostaglandin analogues with cervical contractility properties used in combination with mifepristone for medical abortion. Additionally, checkToP® is a low-sensitivity urinary hCG rapid test for home use to confirm pregnancy status. The products are designed for healthcare professionals and their patients, manufactured in Europe to required quality standards, and are available in nearly 40 countries.

Differentiator

Problem solved

Functional benefit

Brands

• Mifegyne®: Active steroid with antiprogesterone activities. Available as 200 mg tablet (box of 3) and 600 mg tablet (single tablet).
• MisoOne®
• Topogyne®
• Mispregnol®
• checkToP®

Products and services

• Mifegyne® 200 mg (mifepristone) Mifegyne® 200 mg is an antiprogestogen steroid tablet formulation of mifepristone (200 mg per tablet), a selective progesterone receptor modulator (SPRM). It is supplied in boxes of 3 tablets and is intended for use by healthcare professionals in medical abortion regimens.
• Mifegyne® 600 mg (mifepristone) Mifegyne® 600 mg is a single-tablet 600 mg formulation of mifepristone, an antiprogestogen steroid with selective progesterone receptor modulator activity, supplied as a box containing one 600 mg tablet for healthcare professional use in medical abortion care.
• MisoOne® / Topogyne® / Mispregnol® (misoprostol 400 µg) A scored 400 µg oral misoprostol tablet (prostaglandin analogue with cervical contractility properties) supplied in boxes of 1 or 16 tablets, intended for use alongside mifepristone in medical abortion regimens. The product is marketed under the names MisoOne®, Topogyne®, or Mispregnol® depending on the country.
• checkToP® (low-sensitivity urinary hCG rapid test)

Quantifiable outcome

• Medical abortion added to WHO Essential Medicines List (2005)

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Nordic PharmacoreChannel Partner/ Reseller/ Distributor · 1 January 2007Nordic Pharma entered into a collaboration with Exelgyn in 2007 for the marketing and distribution of Mifegyne® in Scandinavia. In 2009, this agreement was extended to all European countries. Nordic Pharma subsequently acquired Exelgyn in 2010, making it a wholly-owned subsidiary.
• FIAPAC (International Federation of Abortion & Contraception Professionals)coreStrategic or Co-development PartnerExelgyn maintains an active and lasting collaboration with FIAPAC, a professional organization supporting abortion and contraception professionals. This partnership focuses on professional education, awareness, and advancing medical abortion care standards.

Scale indicators1 record

Recent moves6 records

Expansion highlights3 records

Emerging players

• Cipla: Large Indian generic pharmaceutical company with a women's health portfolio including reproductive therapeutics. Comparable in that it supplies affordable reproductive medicines globally, particularly in emerging markets, though it operates across many other therapeutic categories.

Broad incumbents

• Organon: Global women's health pharmaceutical company spun out of Merck in 2021, with a portfolio spanning contraception, fertility, and biosimilars. Comparable as a broad women's health incumbent with overlapping customer relationships in OB/GYN, though not focused specifically on medical abortion.
• Nordic Pharma: Parent company of Exelgyn and a pan-European specialty pharmaceutical group focused on women's health, gynecology, and niche therapeutics. Nordic Pharma owns and distributes Exelgyn's portfolio, making it the most directly comparable commercial entity, although it operates across multiple therapeutic areas rather than exclusively in reproductive health.
• Bayer Pharmaceuticals: Major pharmaceutical company with significant women's health and reproductive medicine portfolio including contraception and gynecological therapies. Overlaps with Exelgyn in the OB/GYN prescribing community but operates at vastly greater scale and across multiple therapeutic areas.
• AbbVie (via Allergan Aesthetics & Women's Health): Global pharmaceutical company with women's health assets including reproductive and gynecological products. While not focused exclusively on medical abortion, it competes for the same OB/GYN prescribing relationships and women's health formulary slots in major markets.

Direct peers

• Naari: Women's health pharmaceutical company specializing in generic and branded reproductive health products including mifepristone and misoprostol. Competes directly with Exelgyn in tenders and formulary placements, particularly in emerging markets.
• HRA Pharma: European specialty pharmaceutical company with a historic focus on women's health and reproductive care, including emergency contraception (ellaOne®) and reproductive therapeutics. HRA Pharma is the closest direct peer in terms of category, European footprint, and specialty women's health commercial model; acquired by Perrigo in 2022 but operates as a distinct unit.
• GenBioPro: Generic mifepristone manufacturer that gained US FDA approval in 2019. Directly comparable product targeting the same clinical use case and end customer, and represents the principal generic threat to originator mifepristone franchises like Exelgyn's.
• Linepharma: Specialty pharmaceutical company focused on medical abortion and reproductive health, marketing mifepristone and misoprostol regimens in Europe and emerging markets. Directly comparable product portfolio and target customer base (OB/GYNs and women's health clinics).
• Danco Laboratories: US-based pharmaceutical company marketing Mifeprex® (mifepristone), the US brand equivalent of Exelgyn's Mifegyne®. Closely comparable originator product in the largest single market, though currently navigating post-Dobbs US regulatory disruption.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Exelgyn